CSIMarket Company Name, Ticker, Customers, else..
 
Lipella Pharmaceuticals Inc   (LIPO)
 
Price: $0.0005 $0.00 0.000%
Day's High: $0.0005000000237487257 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: 150 %
Volume (M): 0 52 Wk High: $ 0.64
Volume (M$): $ 0 52 Wk Avg: $0.20
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 5
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Lipella Pharmaceuticals Inc is a pharmaceutical company that specializes in the development, manufacturing, and marketing of innovative drugs and therapies. The company focuses on discovering novel solutions to address unmet medical needs and improve patient outcomes. Lipella Pharmaceuticals aims to create breakthrough treatments in areas such as cancer, autoimmune diseases, and rare disorders. They have a team of dedicated professionals including researchers, scientists, and clinicians who collaborate to bring new drugs from concept to commercialization. With a commitment to scientific excellence and patient care, Lipella Pharmaceuticals strives to make a significant impact on global healthcare.


   Company Address: 7800 Susquehanna St. Pittsburgh 15208 PA
   Company Phone Number: 894-1853   Stock Exchange / Ticker: LIPO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMPH   -1.09%    
AMRX   -6.21%    
ANIP   -2.05%    
COLL   -3.5%    
MNK   -39.2%    
UPC   -0.69%    
• View Complete Report
   



Clinical Study

Lipella Pharmaceuticals Leads Innovation in Oral Lichen Planus Therapy and Bladder Imaging Breakthroughs,

Published Tue, Apr 22 2025 10:29 AM UTC

Lipella Pharmaceuticals Advances in Oral Lichen Planus Treatment and Bladder Imaging Technology Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has announced significant advancements in its clinical trials and imaging techniques, positioning itself at the forefront of medical innovation. Notably, the company has reported positive results from the second coho...
Management Announcement

Lipella Pharmaceuticals: A Promising Drug Pursuit Shrouded in Financial Uncertainty,

Published Mon, Mar 31 2025 3:00 PM UTC

Lipella Pharmaceuticals Faces Financial Challenges Amid Promising Drug DevelopmentIn a recent appearance on the Pharmaverse podcast, Michael Chancellor, co-founder of Lipella Pharmaceuticals, discussed the company’s innovative pursuit of new therapeutic solutions, notably the LP-310, aimed at treating oral lichen planus (OLP). However, while the enthusiasm surrounding Li...
Clinical Study

Advancing Therapeutics Lipella Pharmaceuticals Completes First Cohort of LP-310 in Phase 2a Clinical Trial for Oral L...

Published Thu, Nov 21 2024 10:30 AM UTC

Lipella Pharmaceuticals recently announced the successful completion of the first cohort in its Phase 2a clinical trial investigating LP-310, a novel therapeutic candidate aimed at treating oral lichen planus (OLP). Following the first cohort s analysis, the study will transition to evaluate the next dose group, signaling a pivotal moment in the potential treatment landsc...
Clinical Study

Lipella Pharmaceuticals Reports Positive Early Tolerability Outcomes in Phase 2a Trial of LP-310 for Oral Lichen Planus

Published Tue, Sep 24 2024 12:01 PM UTC

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) has announced promising early results from its Phase 2a clinical trial of LP-310, a novel treatment for Oral Lichen Planus (OLP). The study, which primarily focuses on the tolerability of the investigational drug, showed encouraging outcomes, suggesting that LP-310 could hold significant potential for patients suffering from this d...
Clinical Study

Lipella Pharmaceuticals Advances Bladder Imaging at ICICJ Conference Amid Financial Struggles,

Published Wed, Aug 21 2024 9:00 AM UTC

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference Lipella Pharmaceuticals Inc., a leading innovator in urological health, has announced a breakthrough in bladder imaging technology at the International Conference on Innovations in Clinical Journeys (ICICJ). This new technique is poised to revolutionize the way bladder conditions are diagn...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.01
Price to Sales (Expected) -
Price to Book 0
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.89
Working Capital Ratio 3.24
Leverage Ratio (MRQ) 0.58
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.61 $
Revenues (TTM) 0.09 $
Cash Flow (TTM) 0.11 $
Cash 0.41 $
Book Value 0.33 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -333,110
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.